世界の組換え非グリコシル化タンパク質バイオシミラー市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4957 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、組換え非グリコシル化タンパク質バイオシミラーのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（インスリン、rHGH、インターフェロン）、用途別市場規模（腫瘍、慢性疾患、自己免疫疾患、血液疾患、成長ホルモン欠乏症、感染症、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・組換え非グリコシル化タンパク質バイオシミラーの市場動向 ・企業の競争状況、市場シェア ・組換え非グリコシル化タンパク質バイオシミラーの種類別市場規模（インスリン、rHGH、インターフェロン） ・組換え非グリコシル化タンパク質バイオシミラーの用途別市場規模（腫瘍、慢性疾患、自己免疫疾患、血液疾患、成長ホルモン欠乏症、感染症、その他） ・組換え非グリコシル化タンパク質バイオシミラーの北米市場規模2016-2027（アメリカ、カナダ） ・組換え非グリコシル化タンパク質バイオシミラーのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・組換え非グリコシル化タンパク質バイオシミラーのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・組換え非グリコシル化タンパク質バイオシミラーの中南米市場規模2016-2027（メキシコ、ブラジル） ・組換え非グリコシル化タンパク質バイオシミラーの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Sandoz、Pfizer、Teva Pahrmaceutical、Celltrion、Biocon、Amgen、Samsung Biologics、Mylan、Dr. Reddy's Laboratories、Stada Arzneimittel AG） ・結論

Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor, interferons, and insulin. The statistic scope in this report is Recombinant non-glycosylated proteins biosimilars.

Market Analysis and Insights: Global Recombinant Non-Glycosylated Proteins Biosimilars Market
The global Recombinant Non-Glycosylated Proteins Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Non-Glycosylated Proteins Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Non-Glycosylated Proteins Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Non-Glycosylated Proteins Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Non-Glycosylated Proteins Biosimilars market.

Global Recombinant Non-Glycosylated Proteins Biosimilars Scope and Market Size
Recombinant Non-Glycosylated Proteins Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Non-Glycosylated Proteins Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Insulin
rHGH
Interferon

Segment by Application
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Diseases

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sandoz
Pfizer
Teva Pahrmaceutical
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy’s Laboratories

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Insulin
1.2.3 rHGH
1.2.4 Interferon
1.3 Market by Application
1.3.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Chronic Diseases
1.3.4 Autoimmune Diseases
1.3.5 Blood Disorders
1.3.6 Growth Hormone Deficiency
1.3.7 Infectious Diseases
1.3.8 Other Diseases
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Perspective (2016-2027)
2.2 Recombinant Non-Glycosylated Proteins Biosimilars Growth Trends by Regions
2.2.1 Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Share by Regions (2016-2021)
2.2.3 Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Regions (2022-2027)
2.3 Recombinant Non-Glycosylated Proteins Biosimilars Industry Dynamic
2.3.1 Recombinant Non-Glycosylated Proteins Biosimilars Market Trends
2.3.2 Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers
2.3.3 Recombinant Non-Glycosylated Proteins Biosimilars Market Challenges
2.3.4 Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Recombinant Non-Glycosylated Proteins Biosimilars Players by Revenue
3.1.1 Global Top Recombinant Non-Glycosylated Proteins Biosimilars Players by Revenue (2016-2021)
3.1.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Players (2016-2021)
3.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Recombinant Non-Glycosylated Proteins Biosimilars Revenue
3.4 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Concentration Ratio
3.4.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Non-Glycosylated Proteins Biosimilars Revenue in 2020
3.5 Recombinant Non-Glycosylated Proteins Biosimilars Key Players Head office and Area Served
3.6 Key Players Recombinant Non-Glycosylated Proteins Biosimilars Product Solution and Service
3.7 Date of Enter into Recombinant Non-Glycosylated Proteins Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Recombinant Non-Glycosylated Proteins Biosimilars Breakdown Data by Type
4.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Size by Type (2016-2021)
4.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Type (2022-2027)

5 Recombinant Non-Glycosylated Proteins Biosimilars Breakdown Data by Application
5.1 Global Recombinant Non-Glycosylated Proteins Biosimilars Historic Market Size by Application (2016-2021)
5.2 Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2016-2027)
6.2 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type
6.2.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021)
6.2.2 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027)
6.2.3 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2027)
6.3 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application
6.3.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021)
6.3.2 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027)
6.3.3 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2027)
6.4 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country
6.4.1 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2016-2021)
6.4.2 North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2016-2027)
7.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type
7.2.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021)
7.2.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027)
7.2.3 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2027)
7.3 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application
7.3.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021)
7.3.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027)
7.3.3 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2027)
7.4 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country
7.4.1 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2016-2021)
7.4.2 Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2016-2027)
8.2 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type
8.2.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2027)
8.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application
8.3.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2027)
8.4 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region
8.4.1 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2016-2027)
9.2 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type
9.2.1 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021)
9.2.2 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027)
9.2.3 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2027)
9.3 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application
9.3.1 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021)
9.3.2 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027)
9.3.3 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2027)
9.4 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country
9.4.1 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2016-2021)
9.4.2 Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size (2016-2027)
10.2 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type
10.2.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2027)
10.3 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application
10.3.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2027)
10.4 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country
10.4.1 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sandoz
11.1.1 Sandoz Company Details
11.1.2 Sandoz Business Overview
11.1.3 Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.1.4 Sandoz Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.1.5 Sandoz Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.2.4 Pfizer Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Teva Pahrmaceutical
11.3.1 Teva Pahrmaceutical Company Details
11.3.2 Teva Pahrmaceutical Business Overview
11.3.3 Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.3.4 Teva Pahrmaceutical Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.3.5 Teva Pahrmaceutical Recent Development
11.4 Celltrion
11.4.1 Celltrion Company Details
11.4.2 Celltrion Business Overview
11.4.3 Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.4.4 Celltrion Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.4.5 Celltrion Recent Development
11.5 Biocon
11.5.1 Biocon Company Details
11.5.2 Biocon Business Overview
11.5.3 Biocon Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.5.4 Biocon Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.5.5 Biocon Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.6.4 Amgen Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.6.5 Amgen Recent Development
11.7 Samsung Biologics
11.7.1 Samsung Biologics Company Details
11.7.2 Samsung Biologics Business Overview
11.7.3 Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.7.4 Samsung Biologics Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.7.5 Samsung Biologics Recent Development
11.8 Mylan
11.8.1 Mylan Company Details
11.8.2 Mylan Business Overview
11.8.3 Mylan Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.8.4 Mylan Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.8.5 Mylan Recent Development
11.9 Dr. Reddy’s Laboratories
11.9.1 Dr. Reddy’s Laboratories Company Details
11.9.2 Dr. Reddy’s Laboratories Business Overview
11.9.3 Dr. Reddy’s Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.9.4 Dr. Reddy’s Laboratories Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.9.5 Dr. Reddy’s Laboratories Recent Development
11.10 Stada Arzneimittel AG
11.10.1 Stada Arzneimittel AG Company Details
11.10.2 Stada Arzneimittel AG Business Overview
11.10.3 Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Introduction
11.10.4 Stada Arzneimittel AG Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
11.10.5 Stada Arzneimittel AG Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Insulin
Table 3. Key Players of rHGH
Table 4. Key Players of Interferon
Table 5. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Regions (2016-2021)
Table 9. Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Regions (2022-2027)
Table 11. Recombinant Non-Glycosylated Proteins Biosimilars Market Trends
Table 12. Recombinant Non-Glycosylated Proteins Biosimilars Market Drivers
Table 13. Recombinant Non-Glycosylated Proteins Biosimilars Market Challenges
Table 14. Recombinant Non-Glycosylated Proteins Biosimilars Market Restraints
Table 15. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Players (2016-2021)
Table 17. Global Top Recombinant Non-Glycosylated Proteins Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Non-Glycosylated Proteins Biosimilars as of 2020)
Table 18. Ranking of Global Top Recombinant Non-Glycosylated Proteins Biosimilars Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Recombinant Non-Glycosylated Proteins Biosimilars Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Recombinant Non-Glycosylated Proteins Biosimilars Product Solution and Service
Table 22. Date of Enter into Recombinant Non-Glycosylated Proteins Biosimilars Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Type (2016-2021)
Table 26. Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Application (2016-2021)
Table 30. Global Recombinant Non-Glycosylated Proteins Biosimilars Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 62. Sandoz Company Details
Table 63. Sandoz Business Overview
Table 64. Sandoz Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 65. Sandoz Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 66. Sandoz Recent Development
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 70. Pfizer Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Teva Pahrmaceutical Company Details
Table 73. Teva Pahrmaceutical Business Overview
Table 74. Teva Pahrmaceutical Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 75. Teva Pahrmaceutical Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 76. Teva Pahrmaceutical Recent Development
Table 77. Celltrion Company Details
Table 78. Celltrion Business Overview
Table 79. Celltrion Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 80. Celltrion Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 81. Celltrion Recent Development
Table 82. Biocon Company Details
Table 83. Biocon Business Overview
Table 84. Biocon Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 85. Biocon Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 86. Biocon Recent Development
Table 87. Amgen Company Details
Table 88. Amgen Business Overview
Table 89. Amgen Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 90. Amgen Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 91. Amgen Recent Development
Table 92. Samsung Biologics Company Details
Table 93. Samsung Biologics Business Overview
Table 94. Samsung Biologics Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 95. Samsung Biologics Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 96. Samsung Biologics Recent Development
Table 97. Mylan Company Details
Table 98. Mylan Business Overview
Table 99. Mylan Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 100. Mylan Recent Development
Table 101. Dr. Reddy's Laboratories Company Details
Table 102. Dr. Reddy's Laboratories Business Overview
Table 103. Dr. Reddy's Laboratories Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 104. Dr. Reddy's Laboratories Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 105. Dr. Reddy's Laboratories Recent Development
Table 106. Stada Arzneimittel AG Company Details
Table 107. Stada Arzneimittel AG Business Overview
Table 108. Stada Arzneimittel AG Recombinant Non-Glycosylated Proteins Biosimilars Product
Table 109. Stada Arzneimittel AG Revenue in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021) & (US$ Million)
Table 110. Stada Arzneimittel AG Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Type: 2020 VS 2027
Figure 2. Insulin Features
Figure 3. rHGH Features
Figure 4. Interferon Features
Figure 5. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application: 2020 VS 2027
Figure 6. Oncology Case Studies
Figure 7. Chronic Diseases Case Studies
Figure 8. Autoimmune Diseases Case Studies
Figure 9. Blood Disorders Case Studies
Figure 10. Growth Hormone Deficiency Case Studies
Figure 11. Infectious Diseases Case Studies
Figure 12. Other Diseases Case Studies
Figure 13. Recombinant Non-Glycosylated Proteins Biosimilars Report Years Considered
Figure 14. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Regions: 2020 VS 2027
Figure 17. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Regions (2022-2027)
Figure 18. Global Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Players in 2020
Figure 19. Global Top Recombinant Non-Glycosylated Proteins Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Non-Glycosylated Proteins Biosimilars as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Recombinant Non-Glycosylated Proteins Biosimilars Revenue in 2020
Figure 21. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Type (2016-2021)
Figure 22. Global Recombinant Non-Glycosylated Proteins Biosimilars Revenue Market Share by Type (2022-2027)
Figure 23. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Type (2016-2027)
Figure 25. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application (2016-2027)
Figure 26. North America Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Country (2016-2027)
Figure 27. United States Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Type (2016-2027)
Figure 31. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application (2016-2027)
Figure 32. Europe Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Country (2016-2027)
Figure 33. Germany Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Region (2016-2027)
Figure 43. China Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Type (2016-2027)
Figure 51. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application (2016-2027)
Figure 52. Latin America Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Country (2016-2027)
Figure 53. Mexico Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Recombinant Non-Glycosylated Proteins Biosimilars Market Share by Country (2016-2027)
Figure 59. Turkey Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Recombinant Non-Glycosylated Proteins Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Sandoz Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 64. Teva Pahrmaceutical Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 65. Celltrion Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 66. Biocon Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 67. Amgen Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 68. Samsung Biologics Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 69. Mylan Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 70. Dr. Reddy's Laboratories Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 71. Stada Arzneimittel AG Revenue Growth Rate in Recombinant Non-Glycosylated Proteins Biosimilars Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

---